Icos Corporation
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Icos ranks #29,041 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.
- #29,041
- of 49,997 US assignees by volume
- 8th percentile
- by Innovation Score (20.9/100)
- 7.1
- avg claims per patent
- -71%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R29041 · US Corporation #29,041 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 9 grants
- MID-PACK #29,041/49,997
- PHOTO-FINISH ICA TriNova
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 20.9/100
- CLAIMS-SPARSE 7.1 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -71% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: ICA TriNova, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Icos’s 20.9 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Icos
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Icos · this assignee 21
Icos · this assignee
21 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Icos's Innovation Score is 20.9/100 (8th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Icos?
Each dot is one of Icos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Icos’s own 7.1 claims/patent is at or below the 11.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Icos's grants concentrate
Icos Corporation is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2016. By volume, Icos sits between ICA TriNova, LLC and Ifco Systems GMBH.
Who files at Icos's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- ICA Trinova
ICA TriNova, LLC
9 patents
- Icare Finland OY
Icare Finland OY
9 patents
- ICG Licensing
ICG Licensing LLC
9 patents
- Icon Bioscience
Icon Bioscience, Inc.
9 patents
- ID Pharma
ID Pharma Co., Ltd.
9 patents
- IDM Global
IDM Global, Inc.
9 patents
- Idsc Holdings
Idsc Holdings LLC
9 patents
- Ifco Systems
Ifco Systems GMBH
9 patents
- Icos ◀
Icos Corporation
9 patents
What this shows Icos holds 9 patents at rank #29,025, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Icos
By rank, the assignees closest to #29,025 in granted patent volume.
- ICA TriNova, LLC #29,021 · 9 patents
- Icare Finland OY #29,022 · 9 patents
- ICG Licensing LLC #29,023 · 9 patents
- Icon Bioscience, Inc. #29,024 · 9 patents
- ID Pharma Co., Ltd. #29,026 · 9 patents
- IDM Global, Inc. #29,027 · 9 patents
- Idsc Holdings LLC #29,028 · 9 patents
- Ifco Systems GMBH #29,029 · 9 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Icos's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Icos's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
21 8th percentile higher than 8% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 33.3% |
| 2016 | 1 | 11.1% |
| 2018 | 1 | 11.1% |
| 2019 | 2 | 22.2% |
| 2020 | 1 | 11.1% |
| 2021 | 1 | 11.1% |
Which technologies does Icos Corporation patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Icos Corporation's patent record in context - here's where to go next.
- Icos Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #29,041 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Icos Corporation against ICA TriNova, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 20.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.